Key result
Combination antianginal therapy linked to ~1.2-point reduction in angina functional class.
Why the study?
This study aimed to evaluate the efficacy and tolerability of different classes of antianginal drugs in patients with chronic coronary artery disease, type 2 diabetes mellitus, and stable angina pectoris.
Observational (n=104)
Answers are grounded in this paper and cite their sources.
Demonstrates rapid reduction in chest pain severity in type 2 diabetes with combination antianginal regimens, highlighting effective symptom management.
The purpose — to study the efficacy and tolerability of different classes of antianginal drugs in patients with chronic coronary artery disease with DM2 having stable angina pectoris syndrome. Material and methods. 104 patients (m/w 59/45, average age — 64.7 (11.1) years) with DM2 and with stable angina pectoris were under observation. All patients received adequate hypoglycemic, vaso- and cardioprotective therapy. All patients were prescribed antianginal agents in various combinations: β-AB — in 32 (30.8%) cases, calcium channel blockers — in 30 (28.8%), ivabradine — in 29 (27.9%), ranolazine — in 25 (24.0%), nitrates — in 22 (21.2%), trimetazidine — in 38 (36.5%), and meldonium — in 34 (32.7%) cases. Before the start of follow-up and after 16 weeks of treatment the angina pectoris class and standard clinical and biochemical parameters were evaluated, echocardiographic examination, Holter monitoring of an electrocardiogram, a test with reactive hyperemia were performed. Results. The treatment provided a rapid, distinct and stable antianginal effect. Thus, the average levels of angina pectoris decreased from 2.37 (0.4) to 1.19 (0.1), p < 0.05. A significant decrease in clinical manifestations of angina pectoris was achieved after 2 weeks from the start of treatment in 72 (69.2%), and after 4 weeks — in 93 (89.4%) people. A reliable relationship between the higher antianginal efficacy of treatment and some clinical and laboratory features of patients was revealed. Conclusions. In individuals with stable angina and DM2, adequate use of antianginal drugs provides a rapid and stable decrease in the severity of angina.
No takes yet. Share an insight, caveat, or question.
Mykhailichenko et al. (2022) conducted an observational in Chronic coronary artery disease with type 2 diabetes mellitus and stable angina pectoris (n=104). Combination antianginal therapy (beta-blockers, calcium channel blockers, ivabradine, ranolazine, nitrates, trimetazidine, meldonium) vs. Baseline (pre-treatment) was evaluated on Angina pectoris functional class / clinical manifestations of angina pectoris (p=<0.05). Combination antianginal therapy decreased average angina pectoris class from 2.37 to 1.19, reducing clinical manifestations in 89.4% of patients at 4 weeks.
Synapse has enriched 10 related papers. Consider them for comparative context: